CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Anthracycline & Cyclophosphamide treatment scheme +10 moredrug
Likely dose
Anthracycline & Cyclophosphamide treatment scheme 60mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04568161
NCT04568161N/ACompleted

Chronic Effect of Doxorubicin and Cyclophosphamide on Neurovascular Control and Blood Pressure in Women in Adjuvant Treatment for Breast Neoplasia

University of Sao Paulo General Hospital·interventional·Posted Sep 29, 2020·Updated Apr 3, 2025

In Brief

A clinical study evaluating Physical Characteristics, Muscular Sympathetic Nervous Activity, and 9 other interventions for Cardiotoxicity and 4 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The present study aims to investigate the chronic effect of treatment with doxorubicin and cyclophosphamide on neurovascular control and blood pressure in women undergoing adjuvant treatment for breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBrazil

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedSep 29, 2020
Enrollment StartAug 3, 2020
Primary CompletionSep 3, 2022
Study CompletionMar 3, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.8 years ago

Interventions

Physical Characteristicsprocedure

Body weight, height and waist circumference

Muscular Sympathetic Nervous Activityprocedure

Microneurography technique.

Cardiac Functionother

Echocardiography.

Heart rateother

Electrocardiography

Blood pressureother

Non-invasive photoplethysmography.

Blood Assessmentsother

Serum and Plasma will be extracted by centrifugation. Endothelial microparticles by flow cytometry Interleukin-6 and tumor necrosis factor α by ELISA, High-sensitive reactive serum C-reactive protein by immunoturbidimetric assay, NT- ProBNP According to Central Laboratory, Hospital das Clinicas, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo. Endothelin-1 by immunoenzymatic method Nitric oxide by gas chemiluminescence Lipoperoxidation by fluorimetry Carbonyl by spectrophotometer, and Superoxide Dismutase (SOD) by colorimetry.

Muscle blood flowother

Venous occlusion plethysmography

Endothelium-dependent vascular functionother

Brachial ultrasound

Vascular intima-media thicknessother

Carotid ultrasound

Physical Capacityother

Cardiopulmonary exercise test

Anthracycline & Cyclophosphamide treatment schemedrug

Four session of intravenous (in bolus) infusion of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 with an interval of 21 days between sessions.